| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's | N/A | Compedica Inc | <1 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| Evaluation of an Online Prostate Cancer Screening Decision Aid | N/A | David Siegel | <1 mi |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | N/A | CrannMed | <1 mi |
| A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | Phase 2 | Debiopharm International SA | <1 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | <1 mi |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Groningen International Study on Sentinel Nodes in Vulvar Cancer-III | Phase 2 | University Medical Center Groningen | <1 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx | N/A | Duke University | <1 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | <1 mi |
| Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry | — | Duke University | <1 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Sacral Neuromodulation for Male Overactive Bladder (MOAB) | N/A | Axonics, Inc. | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System | N/A | May Health | <1 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | <1 mi |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | Phase 3 | NRG Oncology | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| Registry of Older Patients With Cancer | — | UNC Lineberger Comprehensive Cancer Center | <1 mi |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | ImmunityBio, Inc. | <1 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | <1 mi |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 2 | Tyra Biosciences, Inc | <1 mi |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | <1 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | <1 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | <1 mi |
| Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers | N/A | LifeNet Health | <1 mi |
| A Food As Medicine Approach to Address Food Insecurity in Rural North Carolina | N/A | North Carolina State University | <1 mi |
| Assessment of AI Program 'DRISTi' as a Screening Tool | — | Artelus AI | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers | N/A | Tides Medical | <1 mi |
| A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL | Phase 4 | HealthTech Wound Care | <1 mi |
| Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus | Phase 2 | Hanmi Pharmaceutical Company Limited | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | <1 mi |
| Late Onset Alzheimer's Disease | — | Columbia University | <1 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | <1 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | <1 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | <1 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | <1 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | <1 mi |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase 3 | Population Health Research Institute | <1 mi |
| HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry | — | University of Kansas Medical Center | <1 mi |
| Product Surveillance Registry | — | Medtronic | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | <1 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | <1 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | <1 mi |
| FORWARD CAD IDE Study | N/A | Shockwave Medical, Inc. | <1 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | <1 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D, Inc. | <1 mi |
| Finding Correlations Between Asthma Exacerbation, Physiological Measurements and Environmental Factors | — | North Carolina State University | <1 mi |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Phase 1 | Amgen | <1 mi |
| A Study to Evaluate Solriktug in Adult Participants With Asthma | Phase 2 | Uniquity One (UNI) | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Phase 3 | Cerevance | <1 mi |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | AbbVie | <1 mi |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | <1 mi |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Phase 3 | TG Therapeutics, Inc. | <1 mi |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | <1 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA | N/A | UNC Lineberger Comprehensive Cancer Center | <1 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | <1 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| Shield Post-Approval Study Protocol | — | Guardant Health, Inc. | 8 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | 8 mi |
| Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment | Phase 3 | University of Rochester NCORP Research Base | 8 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | 8 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | 8 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | 8 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Phase 3 | Xenon Pharmaceuticals Inc. | 8 mi |
| MAINTAIN (Mucosal AblatIoN Therapy After INcretins) | N/A | Dr. Christopher McGowan | 8 mi |
| Fundus Ablation Registry (Gastric Fundus Mucosal Ablation for Weight Loss) | — | True You Weight Loss | 8 mi |
| Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss) | — | True You Weight Loss | 8 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | 8 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | 8 mi |
| Study of JK07 in Patients With Chronic Heart Failure | Phase 2 | Salubris Biotherapeutics Inc | 8 mi |
| Embo Registry; National Registry for Artery Embolization | — | Vascular Solutions of North Carolina | 8 mi |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 | VistaGen Therapeutics, Inc. | 8 mi |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | NovoCure GmbH | 8 mi |
| CivaDerm(TM) Surface Therapy Pilot Study | Early 1 | CivaTech Oncology | 11 mi |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | Phase 3 | Grifols Therapeutics LLC | 11 mi |
| Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test | — | Mainz Biomed | 11 mi |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Lexicon Pharmaceuticals | 11 mi |
| A Phase 2 Study of CRD-4730 in CPVT | Phase 2 | Cardurion Pharmaceuticals, Inc. | 11 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | 11 mi |
| Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications | — | AbbVie | 11 mi |
| Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System | N/A | DT MedTech, LLC | 11 mi |
| Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty) | — | Zimmer Biomet | 11 mi |
| A Study of NE3107 in Early Parkinson's | Phase 2 | BioVie Inc. | 11 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | 11 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | 11 mi |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | Mirum Pharmaceuticals, Inc. | 11 mi |
| NHALES (Natural History of Asthma With Longitudinal Environmental Sampling) | — | National Institute of Environmental Health Sciences (NIEHS) | 15 mi |
| Personalized Environment and Genes Study | — | National Institute of Environmental Health Sciences (NIEHS) | 15 mi |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin | — | National Institute of Environmental Health Sciences (NIEHS) | 15 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | 21 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | 21 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | 21 mi |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Phase 3 | Alliance for Clinical Trials in Oncology | 21 mi |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | 21 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Immunovant Sciences GmbH | 21 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | 21 mi |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | 21 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | 21 mi |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | 21 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | 21 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | 21 mi |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | Phase 1 | Valent Technologies, LLC | 21 mi |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Phase 1/2 | Replimune Inc. | 21 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | 21 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | 21 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | 21 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | 21 mi |
| A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | 21 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | 21 mi |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | Phase 3 | AbbVie | 21 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | 21 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | N/A | Massachusetts General Hospital | 21 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | 21 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | 21 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | 21 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | 21 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | 21 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Phase 3 | Alliance for Clinical Trials in Oncology | 21 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | 21 mi |
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | 21 mi |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients | Phase 1/2 | Karyopharm Therapeutics Inc | 21 mi |
| A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | BeOne Medicines | 21 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | 21 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | 21 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | 21 mi |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | 21 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | 21 mi |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 21 mi |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | AbbVie | 21 mi |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Kyntra Bio | 21 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | 21 mi |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | 21 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | 21 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | 21 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | 21 mi |
| A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | GentiBio, Inc | 21 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | 21 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | 21 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 21 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | 21 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | 21 mi |
| A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | Phase 2 | AskBio Inc | 21 mi |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/3 | Biogen | 21 mi |
| Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | Phase 1/2 | Colette Shen | 21 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | 21 mi |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Phase 2 | Laura Huppert, MD, BA | 21 mi |
| Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring | — | Carevive Systems, Inc. | 21 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | 21 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | 21 mi |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/3 | IDEAYA Biosciences | 21 mi |
| SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery | Phase 1 | SURGE Therapeutics | 21 mi |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | Genmab | 21 mi |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | Phase 2 | VA Office of Research and Development | 21 mi |
| Meaning-Centered Pain Coping Skills Training for Cancer Pain | N/A | Duke University | 21 mi |
| QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | Phase 1 | Quanta Therapeutics | 21 mi |
| A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma | Phase 1/2 | April Salama, M.D. | 21 mi |
| Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | Phase 1 | Herbert Lyerly | 21 mi |
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | Phase 1/2 | University of Alabama at Birmingham | 21 mi |
| TOP 2301: Neoadjuvant Chemo for NSCLC | Phase 2 | Duke University | 21 mi |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | Phase 2 | Amgen | 21 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | Phase 1 | Kumquat Biosciences Inc. | 21 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | Phase 1/2 | Hoffmann-La Roche | 21 mi |
| Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study | Phase 4 | Duke University | 21 mi |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase 2 | IDEAYA Biosciences | 21 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | 21 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | 21 mi |
| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | 21 mi |
| A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) | Phase 2 | Genentech, Inc. | 21 mi |
| Autus Valve Pivotal Study | N/A | Autus Valve Technologies, Inc. | 21 mi |
| Treating Psychosocial Distress in Glaucoma | N/A | Duke University | 21 mi |
| Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis | Phase 4 | Novartis Pharmaceuticals | 21 mi |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | Phase 2 | AstraZeneca | 21 mi |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Phase 1 | Boehringer Ingelheim | 21 mi |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | 21 mi |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | Phase 2 | Mirati Therapeutics Inc. | 21 mi |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | 21 mi |
| Intent of Surgery for IPMN | — | NYU Langone Health | 21 mi |
| Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment | N/A | Duke University | 21 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | 21 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | 21 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | 21 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | 21 mi |
| A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Phase 3 | Janssen Research & Development, LLC | 21 mi |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Phase 1 | Oryzon Genomics S.A. | 21 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | 21 mi |
| Preserving Physical Function in Older Adults With Cancer: Impact of an Optimizing Nutrition Intervention Applied Before and After Surgery | N/A | VA Office of Research and Development | 21 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | 21 mi |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | — | Novartis Pharmaceuticals | 21 mi |
| Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | Phase 3 | GlaxoSmithKline | 21 mi |
| Study of Olutasidenib and Temozolomide in HGG | Phase 2 | Rigel Pharmaceuticals | 21 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | 21 mi |
| Exercise and Soft Tissue Sarcoma | N/A | Duke University | 21 mi |
| A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC | Phase 2/3 | Urovant Sciences GmbH | 21 mi |
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed | Phase 1/2 | GlaxoSmithKline | 21 mi |
| COMPASS Study for Metastatic Castration-resistant Prostate Cancer | — | Duke University | 21 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | 21 mi |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | 21 mi |
| Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy | N/A | Medical University of South Carolina | 21 mi |
| Neuroblastoma Maintenance Therapy Trial | Phase 2 | Giselle Sholler | 21 mi |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | 21 mi |
| A Study of PHST001 in Advanced Solid Tumors | Phase 1 | Pheast Therapeutics | 21 mi |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1 | Cullinan Therapeutics Inc. | 21 mi |
| D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | Phase 1/2 | Darell Bigner | 21 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 21 mi |
| Pain With Dementia | N/A | Duke University | 21 mi |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | Phase 4 | Eli Lilly and Company | 21 mi |
| A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | Phase 2 | Children's Oncology Group | 21 mi |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 21 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Phase 3 | Merck Sharp & Dohme LLC | 21 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | 21 mi |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | 21 mi |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Servier Bio-Innovation LLC | 21 mi |
| A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy | Phase 1 | Duke University | 21 mi |
| Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 | Phase 1 | Duke University | 21 mi |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase 2 | University of California, San Francisco | 21 mi |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | Caribou Biosciences, Inc. | 21 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 21 mi |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | — | Tufts Medical Center | 21 mi |
| Prescription of Letrozole for Uterine Myoma | Phase 4 | University of California, San Francisco | 21 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | 21 mi |
| Pharmacokinetics of Drugs Administered to Children | — | Duke University | 21 mi |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression | Phase 1/2 | AstraZeneca | 21 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | 21 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | 21 mi |
| Pilot Study for Speculum Free Cervical Cancer Screening | N/A | Duke University | 21 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | 21 mi |
| Key Longitudinal Associations With Risk and Glioblastoma Outcomes | — | Duke University | 21 mi |
| Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | 21 mi |
| A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | 21 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | 21 mi |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Phase 1 | Sabine Mueller, MD, PhD | 21 mi |
| Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes | Phase 2 | Stephen Freedland | 21 mi |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | Phase 1 | Darell Bigner | 21 mi |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | 21 mi |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Phase 1 | MacroGenics | 21 mi |
| REMASTer: REcurrent Brain Metastases After SRS Trial | N/A | Monteris Medical | 21 mi |
| Urine Methylation Markers in UTUC | N/A | Duke University | 21 mi |
| Cervical Cancer Detection Using Optical Spectroscopy | N/A | Duke University | 21 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | 21 mi |
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | Phase 1 | Katy Peters, MD, PhD | 21 mi |
| Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors | — | Duke University | 21 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 21 mi |
| D2C7-IT + 2141-V11 Combination Post-resection in rGBM | Phase 1 | Darell Bigner | 21 mi |
| Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method? | — | Duke University | 21 mi |
| A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | Phase 2 | M.D. Anderson Cancer Center | 21 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | 21 mi |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Phase 1 | Carna Biosciences, Inc. | 21 mi |
| A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | Phase 2 | Kahr Bio Australia Pty Ltd | 21 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | 21 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | 21 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | 21 mi |
| ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | 21 mi |
| A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | 21 mi |
| Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | Phase 1/2 | SWOG Cancer Research Network | 21 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | 21 mi |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | Phase 3 | Novartis Pharmaceuticals | 21 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | 21 mi |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | AbbVie | 21 mi |
| Study of SGR-1505 in Mature B-Cell Neoplasms | Phase 1 | Schrödinger, Inc. | 21 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | 21 mi |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | Phase 1/2 | Memorial Sloan Kettering Cancer Center | 21 mi |
| A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | Phase 2 | Cedars-Sinai Medical Center | 21 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | 21 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | 21 mi |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Phase 1 | Sapience Therapeutics | 21 mi |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Phase 1/2 | Alliance Foundation Trials, LLC. | 21 mi |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Phase 4 | Eli Lilly and Company | 21 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | 21 mi |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Karyopharm Therapeutics Inc | 21 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | 21 mi |
| ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Phase 2 | Nationwide Children's Hospital | 21 mi |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | 21 mi |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | 21 mi |
| Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies | — | Duke University | 21 mi |
| Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 | Phase 1/2 | Pathos AI, Inc. | 21 mi |
| Novel Digital Application for Patients With Acute Leukemia | N/A | Massachusetts General Hospital | 21 mi |
| A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) | Phase 1 | K36 Therapeutics, Inc. | 21 mi |
| Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults | Phase 2 | Sabine Mueller, MD, PhD | 21 mi |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Phase 2 | University of Michigan Rogel Cancer Center | 21 mi |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Phase 3 | Amgen | 21 mi |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Jazz Pharmaceuticals | 21 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | 21 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | 21 mi |
| A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial | Phase 2 | Duke University | 21 mi |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Phase 2/3 | Blueprint Medicines Corporation | 21 mi |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Phase 3 | Amgen | 21 mi |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase 1/2 | Corbus Pharmaceuticals Inc. | 21 mi |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | Phase 2 | Disc Medicine, Inc | 21 mi |
| A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | Phase 3 | Daiichi Sankyo | 21 mi |
| A Study of ZN-c3 in Patients With Ovarian Cancer | Phase 1 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 21 mi |
| HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT | Early 1 | Duke University | 21 mi |
| The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis | N/A | Ad scientiam | 21 mi |
| Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology) | N/A | Medtronic - MITG | 21 mi |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | Phase 2 | Genentech, Inc. | 21 mi |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Phase 4 | Pfizer | 21 mi |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | Phase 1 | USWM CT, LLC | 21 mi |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | 21 mi |
| A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity | Phase 2 | Janssen Research & Development, LLC | 21 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | 21 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | 21 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | 21 mi |
| Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | Phase 1/2 | Baylor College of Medicine | 21 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | 21 mi |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Phase 3 | Day One Biopharmaceuticals, Inc. | 21 mi |
| REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors | N/A | Dana-Farber Cancer Institute | 21 mi |
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | Phase 2 | Giselle Sholler | 21 mi |
| HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM | Phase 2 | Duke University | 21 mi |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | Phase 3 | Mayo Clinic | 21 mi |
| Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | Phase 2 | AstraZeneca | 21 mi |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | K36 Therapeutics, Inc. | 21 mi |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | Phase 3 | Regeneron Pharmaceuticals | 21 mi |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | Phase 3 | Ivy Brain Tumor Center | 21 mi |
| Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2 | N/A | Duke University | 21 mi |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | Phase 3 | M.D. Anderson Cancer Center | 21 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | 21 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | 21 mi |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | 21 mi |
| A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer | Phase 1/2 | SURGE Therapeutics | 21 mi |
| A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | Phase 2 | Day One Biopharmaceuticals, Inc. | 21 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | 21 mi |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | 21 mi |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Phase 3 | Clarity Pharmaceuticals Ltd | 21 mi |
| A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | Phase 2 | VA Office of Research and Development | 21 mi |
| Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer | Phase 2 | Syntrix Biosystems, Inc. | 21 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | 21 mi |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 1 | Bristol-Myers Squibb | 21 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | 21 mi |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | 21 mi |
| Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria | — | Pacific Edge Limited | 21 mi |
| Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking | — | Duke University | 21 mi |
| Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) | Phase 2 | Convergent Therapeutics | 21 mi |
| Lerapolturev (PVSRIPO) in GBM | Phase 2 | Darell Bigner | 21 mi |
| Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | Early 1 | Nationwide Children's Hospital | 21 mi |
| APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Early 1 | Ascentage Pharma Group Inc. | 21 mi |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Phase 1 | Biohaven Therapeutics Ltd. | 21 mi |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | Phase 2/3 | Taiho Oncology, Inc. | 21 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | 21 mi |
| Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | 21 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | 21 mi |
| SPEARHEAD-3 Pediatric Study | Phase 1/2 | USWM CT, LLC | 21 mi |
| Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/3 | Daiichi Sankyo | 21 mi |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | 21 mi |
| CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 1 | Catapult Therapeutics | 21 mi |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Phase 1 | Newave Pharmaceutical Inc | 21 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | 21 mi |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | 21 mi |
| Family Building Decision Support for Female Adolescent and Young Adult Cancer Survivors | N/A | Duke University | 21 mi |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 21 mi |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Phase 2 | Nationwide Children's Hospital | 21 mi |
| Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN) | N/A | Medstar Health Research Institute | 21 mi |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | Phase 3 | Merck Sharp & Dohme LLC | 21 mi |
| Pilot Study of Mindset Moments Among Adolescent and Young Adult Cancer Survivors | N/A | Duke University | 21 mi |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Phase 1/2 | Phanes Therapeutics | 21 mi |
| A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Phase 1 | Amgen | 21 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | 21 mi |
| DALY II USA/ MB-CART2019.1 for DLBCL | Phase 2 | Miltenyi Biomedicine GmbH | 21 mi |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Aptose Biosciences Inc. | 21 mi |
| Cancer and Mild Cognitive Impairment Dyadic Intervention | N/A | Duke University | 21 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | 21 mi |
| High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers | Phase 2 | VA Office of Research and Development | 21 mi |
| Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections | N/A | Medtronic - MITG | 21 mi |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | — | Incyte Corporation | 21 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | 21 mi |
| Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer | — | Duke University | 21 mi |
| Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | Phase 1/2 | Merck Sharp & Dohme LLC | 21 mi |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | Phase 1/2 | Regeneron Pharmaceuticals | 21 mi |
| ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials | — | Duke University | 21 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | 21 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | 21 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | 21 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | 21 mi |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | Phase 1 | Orbus Therapeutics, Inc. | 21 mi |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 21 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | 21 mi |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Early 1 | Nationwide Children's Hospital | 21 mi |
| Excision of Lymph Node Trial (EXCILYNT) (Mel69) | N/A | Craig L Slingluff, Jr | 21 mi |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Phase 2 | Nationwide Children's Hospital | 21 mi |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Kura Oncology, Inc. | 21 mi |
| Targeted Pediatric High-Grade Glioma Therapy | — | Nationwide Children's Hospital | 21 mi |
| A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 2 | VA Office of Research and Development | 21 mi |
| Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US | — | Duke University | 21 mi |
| Intraoperative OCT Guidance of Intraocular Surgery II | — | Duke University | 21 mi |
| Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. | Phase 1 | David D'Alessio, M.D. | 21 mi |
| Role of Aging and Individual Variation in Exercise Training Responsiveness | N/A | Duke University | 21 mi |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes | Phase 4 | Brigham and Women's Hospital | 21 mi |
| A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers | Phase 2 | Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. | 21 mi |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Phase 3 | NewAmsterdam Pharma | 21 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) | N/A | Duke University | 21 mi |
| Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes | N/A | Duke University | 21 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) | N/A | Duke University | 21 mi |
| Combining rTMS & Aerobic Exercise to Treat Depression and Improve Post-Stroke Walking | N/A | Medical University of South Carolina | 21 mi |
| Allopregnanolone (Zuranolone) in Post-stroke Depression | Phase 2 | Duke University | 21 mi |
| Effect of Acetylcholinesterase Inhibitors on Bone Metabolism | Phase 2 | Duke University | 21 mi |
| A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | Phase 1 | Eli Lilly and Company | 21 mi |
| Preventing Alzheimer's With Cognitive Training | Phase 3 | University of South Florida | 21 mi |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Phase 1 | Eli Lilly and Company | 21 mi |
| ADRC Clinical Cohort (Alzheimer's Disease) | — | Duke University | 21 mi |
| Olfactory Biopsies | N/A | Duke University | 21 mi |
| WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy | Phase 2 | Stephen Freedland | 21 mi |
| Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy | Phase 2 | Endevica Bio | 21 mi |
| XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP) | N/A | XVIVO Perfusion | 21 mi |
| Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers | N/A | Duke University | 21 mi |
| The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial | Phase 4 | VA Office of Research and Development | 21 mi |
| Opportunistic PK/PD Trial in Critically Ill Children (OPTIC) | — | Duke University | 21 mi |
| Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment | N/A | XSpline S.p.A. | 21 mi |
| Splanchnic X: Splanchnic Nerve Block in Heart Failure With Reduced Ejection Fraction | N/A | Duke University | 21 mi |
| Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study) | N/A | Gradient Denervation Technologies | 21 mi |
| Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis | — | Duke University | 21 mi |
| A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Phase 1 | Rocket Pharmaceuticals Inc. | 21 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | 21 mi |
| LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions | Phase 4 | Yale University | 21 mi |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase 3 | Tenax Therapeutics, Inc. | 21 mi |
| Ventripoint Single Ventricle Study | N/A | Duke University | 21 mi |
| Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII) | N/A | Foundry Innovation & Research 1, Limited (FIRE1) | 21 mi |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | 21 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | 21 mi |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | 21 mi |
| Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass | Phase 3 | Octapharma | 21 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | 21 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | 21 mi |
| Sex Differences in Barriers and Participation in Physical Activity During and Following Cardiac Rehabilitation | — | Duke University | 21 mi |
| Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | N/A | BrioHealth Solutions, Inc. | 21 mi |
| Medtronic Cardiac Surgery PMCF Registry | — | Medtronic Cardiac Surgery | 21 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | 21 mi |
| TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I) | N/A | P+F Products + Features USA Inc. | 21 mi |
| Cord Clamping Among Neonates With Congenital Heart Disease | N/A | Carl Backes, MD | 21 mi |
| Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System | Phase 2 | Stanford University | 21 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women | Phase 3 | Weill Medical College of Cornell University | 21 mi |
| A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Phase 2 | Tectonic Therapeutic | 21 mi |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. | Phase 4 | Pfizer | 21 mi |
| The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery | Phase 4 | University of California, San Francisco | 21 mi |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Bristol-Myers Squibb | 21 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | 21 mi |
| PULSED AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | 21 mi |
| BiVACOR® Total Artificial Heart Early Feasibility Study | N/A | BiVACOR Inc. | 21 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | 21 mi |
| Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction | Phase 1 | Sardocor Corp. | 21 mi |
| CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting | — | Corcym S.r.l | 21 mi |
| CTSN Embolic Protection Trial | N/A | Icahn School of Medicine at Mount Sinai | 21 mi |
| PK/PD of Digoxin in Infants With SVHD | Phase 1/2 | Duke University | 21 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | 21 mi |
| Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) | N/A | Annetine Gelijns | 21 mi |
| Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | Phase 1 | Pacira Pharmaceuticals, Inc | 21 mi |
| PRIMARY Ancillary Substudy | N/A | Annetine Gelijns | 21 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | 21 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | 21 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | 21 mi |
| Rare Glycogen Storage Diseases Natural History Study | — | Duke University | 21 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | 21 mi |
| Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study | — | Abbott Medical Devices | 21 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities | Phase 3 | Weill Medical College of Cornell University | 21 mi |
| Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) | Phase 2 | Merck Sharp & Dohme LLC | 21 mi |
| Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients | Phase 2 | Baylor Research Institute | 21 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | 21 mi |
| PKP2-ACM Natural History Study | — | Rocket Pharmaceuticals Inc. | 21 mi |
| Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma | — | Bastiaan Driehuys | 21 mi |
| Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes | Phase 2 | University of Colorado, Denver | 21 mi |
| Mechanistic Study of Inspiratory Training in Childhood Asthma (MICA) | N/A | Duke University | 21 mi |
| Inspiratory Pulmonary Rehabilitation for Children With Obesity and Asthma | N/A | Duke University | 21 mi |
| G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study | N/A | Zimmer Biomet | 21 mi |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | 21 mi |
| Improving Hypertension Control in Rheumatoid Arthritis | N/A | Duke University | 21 mi |
| Exactech Vantage Total Ankle System Post Market Clinical Follow-Up - US Only | — | Exactech | 21 mi |
| A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic | — | Sonoma Biotherapeutics, Inc. | 21 mi |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) | Phase 1 | UCB Biopharma SRL | 21 mi |
| Exactech Shoulder Post Market Clinical Follow-up Study | — | Exactech | 21 mi |
| Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block | — | Duke University | 21 mi |
| Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis | N/A | Duke University | 21 mi |
| SMR Stemless Reverse Vs SMR Reverse Shoulder System | N/A | Limacorporate S.p.a | 21 mi |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Phase 2 | Johns Hopkins University | 21 mi |
| Pulmonary Hypertension SOLAR | Phase 2 | Bastiaan Driehuys | 21 mi |
| Photon-counting CT in Chest Imaging | N/A | Duke University | 21 mi |
| Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia | Phase 2 | Bastiaan Driehuys | 21 mi |
| STRIVE Post-Market Registry Study | — | Olympus Corporation of the Americas | 21 mi |
| Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) | Phase 2 | Connect Biopharm LLC | 21 mi |
| A New Intervention to Improve Function in Veterans With Anxiety and Depression | Phase 2 | VA Office of Research and Development | 21 mi |
| Neurostimulation Versus Therapy for Problems With Emotions | N/A | Duke University | 21 mi |
| Supporting Health in Veterans With Heart Failure | N/A | Florida State University | 21 mi |
| Adaptive Coping Skills Training to Improve Psychological Distress Among Cardiorespiratory Failure Survivors | N/A | Duke University | 21 mi |
| Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study | N/A | Duke University | 21 mi |
| ERP to Improve Functioning in Veterans With OCD | N/A | VA Office of Research and Development | 21 mi |
| SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Immigrant Families | N/A | Duke University | 21 mi |
| Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans | N/A | Duke University | 21 mi |
| A Study of Buntanetap in Participants With PD | Phase 2/3 | Annovis Bio Inc. | 21 mi |
| A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's | Phase 1 | Allyx Therapeutics | 21 mi |
| SAD Study in Patients With Parkinson's Disease and Motor Fluctuations | Phase 1 | Serina Therapeutics | 21 mi |
| A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | — | Bristol-Myers Squibb | 21 mi |
| Maternal Autoimmune Disease Research Alliance (MADRA) Registry | — | Duke University | 21 mi |
| A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 21 mi |
| Intervention to Improve Communication and Medication Adherence in Lupus | N/A | Duke University | 21 mi |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Phase 1 | Fate Therapeutics | 21 mi |
| Duke Lupus Registry | — | Duke University | 21 mi |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | Phase 1 | Allogene Therapeutics | 21 mi |
| An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | Phase 3 | AstraZeneca | 21 mi |
| Retinal Imaging in Neurodegenerative Disease | — | Duke University | 21 mi |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | 21 mi |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | — | Biogen | 21 mi |
| Increasing Germline Genetic Testing for Patients With Cancer | N/A | Josh Peterson | 21 mi |
| Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Phase 2 | BicycleTx Limited | 21 mi |
| Cardiac Outcomes With Near-Complete Estrogen Deprivation | N/A | Duke University | 21 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | 21 mi |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | 21 mi |
| Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer | N/A | Massachusetts General Hospital | 21 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | 21 mi |
| Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors | N/A | Duke University | 21 mi |
| Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) | N/A | University Hospital, Basel, Switzerland | 21 mi |
| SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers | N/A | Beth Israel Deaconess Medical Center | 21 mi |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | Phase 1/2 | Incyclix Bio | 21 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | 21 mi |
| Optimizing Surgical Decisions in Young Adults With Breast Cancer | N/A | Weill Medical College of Cornell University | 21 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | 21 mi |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | Sermonix Pharmaceuticals Inc. | 21 mi |
| Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery | N/A | University Hospital, Basel, Switzerland | 21 mi |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Phase 1/2 | Apollo Therapeutics Ltd | 21 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | 21 mi |
| SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers | Phase 2 | Kathy Miller | 21 mi |
| Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | Phase 3 | Northwestern University | 21 mi |
| X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma | Phase 1 | Immunolight, LLC | 21 mi |
| A Study of a Decision Tool for People Considering Breast Reconstruction Surgery | N/A | Memorial Sloan Kettering Cancer Center | 21 mi |
| Identifying Patterns in the Breath of Individuals With Breast Cancer | — | Breathe BioMedical Inc | 21 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | 21 mi |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | Phase 2 | Sarah Sammons, MD | 21 mi |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | Phase 1 | Plexium, Inc. | 21 mi |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | Phase 1 | Memgen, Inc. | 21 mi |
| S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Phase 1/2 | Servier Bio-Innovation LLC | 21 mi |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | 21 mi |
| Virtual Agent Feasibility in Oncology Patients (NTT Data) | N/A | Duke University | 21 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | 21 mi |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase 3 | Nuvalent Inc. | 21 mi |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | 21 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | 21 mi |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | N/A | VA Office of Research and Development | 21 mi |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Phase 3 | Amgen | 21 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | 21 mi |
| Lung Cancer and Aging: Improving Well-being for Older Adults With Lung Cancer | N/A | Duke University | 21 mi |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Phase 1 | BeiGene | 21 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | 21 mi |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Phase 1 | Pfizer | 21 mi |
| Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers | N/A | City of Hope Medical Center | 21 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | 21 mi |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | Phase 1/2 | Synthekine | 21 mi |
| A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer | Phase 1/2 | Bristol-Myers Squibb | 21 mi |
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | Phase 1 | Calico Life Sciences LLC | 21 mi |
| A Study of PHN-012 in Patients With Advanced Solid Tumors | Phase 1 | Pheon Therapeutics | 21 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | 21 mi |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Xencor, Inc. | 21 mi |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | Phase 1 | Amgen | 21 mi |
| Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | Phase 2 | CatalYm GmbH | 21 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | 21 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | 21 mi |
| Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer | — | Washington University School of Medicine | 21 mi |
| Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | Phase 2 | CatalYm GmbH | 21 mi |
| A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Phase 3 | Bristol-Myers Squibb | 21 mi |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | 21 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | 21 mi |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Phase 1/2 | BioNTech SE | 21 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | 21 mi |
| Engage Psychosocial Intervention for Cancer Symptoms | N/A | Duke University | 21 mi |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 21 mi |
| A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). | Phase 2 | NorthSea Therapeutics B.V. | 21 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 21 mi |
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Phase 3 | Albireo, an Ipsen Company | 21 mi |
| Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support | Phase 2/3 | Protara Therapeutics | 21 mi |
| Observational Pharmaco-Epidemiology Research & Analysis | — | Epividian | 21 mi |
| Functional Assessment in Liver Transplantation | — | University of California, San Francisco | 21 mi |
| Siemens Biomarker Multi-modality | N/A | Duke University | 21 mi |
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Phase 2 | Aligos Therapeutics | 21 mi |
| Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | Phase 2 | Shionogi | 21 mi |
| Androgens and NAFLD Longitudinal Cohort Study | — | University of California, San Francisco | 21 mi |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 21 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | 21 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | 21 mi |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Deciphera Pharmaceuticals, LLC | 21 mi |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 21 mi |
| Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients | N/A | Duke University | 21 mi |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | Phase 2 | Academic and Community Cancer Research United | 21 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | 21 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | 25 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | 25 mi |
| Adaptation and Pilot Testing of a Mindfulness-Based Insomnia and Symptom Management Intervention for Women With Breast Cancer Receiving Treatment in Rural Medically Underserved Areas | N/A | Duke University | 25 mi |
| Mitigating PTSD-CUD After Sexual Assault | Phase 1/2 | University of Nevada, Las Vegas | 25 mi |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Phase 3 | Viatris Innovation GmbH | 25 mi |
| A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 25 mi |
| PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2 | N/A | Weill Medical College of Cornell University | 25 mi |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | AbbVie | 25 mi |
| Web-based Learning Module on Optical Diagnosis of Early Colorectal Cancer | N/A | Althaia Xarxa Assistencial Universitària de Manresa | 25 mi |
| Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | Phase 3 | Alexion Pharmaceuticals, Inc. | 25 mi |
| Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) | Early 1 | University of North Carolina, Chapel Hill | 25 mi |
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Phase 1 | Auron Therapeutics, Inc. | 25 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | 25 mi |
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Phase 3 | Palvella Therapeutics, Inc. | 25 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | Phase 1/2 | AbbVie | 25 mi |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Regeneron Pharmaceuticals | 25 mi |
| Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms | N/A | Case Comprehensive Cancer Center | 25 mi |
| A Study of Revumenib and Mezigdomide in People With Leukemia | Phase 1/2 | Memorial Sloan Kettering Cancer Center | 25 mi |
| Effectiveness of Central Oncology Navigation and the Use of an ORN | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy | Phase 2 | The Hospital for Sick Children | 25 mi |
| SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | Phase 1 | Uma Borate | 25 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | 25 mi |
| Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | N/A | University of Michigan Rogel Cancer Center | 25 mi |
| Young Adult Infusion Space Experience Satisfaction Survey | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | 25 mi |
| Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | 25 mi |
| MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | Phase 2/3 | argenx | 25 mi |
| Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | Phase 2 | NMD Pharma A/S | 25 mi |
| Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas | — | University of Michigan Rogel Cancer Center | 25 mi |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | 25 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | 25 mi |
| Rehabilitation Outcomes Study | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Simple Bone Cysts in Kids | Phase 3 | The Hospital for Sick Children | 25 mi |
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | 25 mi |
| DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | 25 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | 25 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | 25 mi |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | 25 mi |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Phase 1 | Poseida Therapeutics, Inc. | 25 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | 25 mi |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel | Phase 1/2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | 25 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 25 mi |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | 25 mi |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | 25 mi |
| GRID Therapy for Extremity Soft Tissue Sarcoma | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | 25 mi |
| Implementation of an Oral Chemotherapy Adherence Intervention | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | 25 mi |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer | Phase 3 | Canadian Cancer Trials Group | 25 mi |
| Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma | Phase 2 | Alpheus Medical, Inc. | 25 mi |
| Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Multimedia Aid for Genetic Testing in Gynecologic Oncology | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | 25 mi |
| A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Phase 2/3 | Bristol-Myers Squibb | 25 mi |
| Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| mPATH-Cloud for Colorectal Cancer Screening | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | 25 mi |
| CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Phase 1/2 | Vironexis Biotherapeutics Inc. | 25 mi |
| Epcoritamab in Previously Treated WM | Phase 2 | Gottfried von Keudell, MD PhD | 25 mi |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer | Phase 1/2 | Janssen Research & Development, LLC | 25 mi |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | Phase 1 | Ichnos Sciences SA | 25 mi |
| ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | Phase 2 | AbbVie | 25 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) | N/A | National Cancer Institute (NCI) | 25 mi |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Phase 1 | Poseida Therapeutics, Inc. | 25 mi |
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Phase 1 | Accutar Biotechnology Inc | 25 mi |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | Phase 3 | AstraZeneca | 25 mi |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | Phase 1 | Flare Therapeutics Inc. | 25 mi |
| A Study of YL201 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | 25 mi |
| Registry for Adults With Plasma Cell Disorders (PCD's) | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Digital Art Therapy for Young Cancer Survivors | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Phase 2/3 | Inhibrx Biosciences, Inc | 25 mi |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | Phase 3 | Corvus Pharmaceuticals, Inc. | 25 mi |
| Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | Phase 2 | Christine Ryan | 25 mi |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Phase 3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 25 mi |
| A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers | N/A | University of Rochester | 25 mi |
| A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | Phase 1 | Regeneron Pharmaceuticals | 25 mi |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | Phase 1/2 | Sellas Life Sciences Group | 25 mi |
| UNC Metastatic Cancer Radiation Therapy Registry | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | 25 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | 25 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeOne Medicines | 25 mi |
| Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Promoting CT Engagement for Pancreatic Cancer With App | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body | Phase 1/2 | Regeneron Pharmaceuticals | 25 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | 25 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | 25 mi |
| Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors | Phase 1/2 | OncoC4, Inc. | 25 mi |
| Designing Visual Tools to Enhance Cancer Surgeon Decision-making | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | 25 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | 25 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | 25 mi |
| Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Phase 1 | TScan Therapeutics, Inc. | 25 mi |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | Phase 1 | National Cancer Institute (NCI) | 25 mi |
| Brain Slice Explants to Predict Drug Response in Brain Tumors | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | 25 mi |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | Phase 2 | Center for International Blood and Marrow Transplant Research | 25 mi |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | — | Blueprint Medicines Corporation | 25 mi |
| A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas | Phase 1 | Lomond Therapeutics Holdings, Inc. | 25 mi |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Phase 1/2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Digoxin Medulloblastoma Study | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | 25 mi |
| A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | Phase 2 | Memorial Sloan Kettering Cancer Center | 25 mi |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Phase 3 | Italfarmaco | 25 mi |
| Combating Cancer-Related Fatigue: A Personalized Supportive Care Program | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | 25 mi |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Phase 2 | MeiraGTx, LLC | 25 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | 25 mi |
| Neuroblastoma Biology Study | — | New Approaches to Neuroblastoma Therapy Consortium | 25 mi |
| Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | Phase 1/2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | Phase 1 | National Cancer Institute (NCI) | 25 mi |
| MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | March Biosciences Inc | 25 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | 25 mi |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | Phase 1 | National Cancer Institute (NCI) | 25 mi |
| Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | Phase 1 | National Cancer Institute (NCI) | 25 mi |
| Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | Phase 1/2 | Noah Hahn, M.D. | 25 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | 25 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | 25 mi |
| Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC | Early 1 | Presage Biosciences | 25 mi |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early 1 | AIDS Malignancy Consortium | 25 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | 25 mi |
| Obeticholic Acid for Prevention in Barrett's Esophagus | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | 25 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | 25 mi |
| Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| UNC Childhood, Adolescent, and Young Adult Cancer Cohort | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study | Phase 1/2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | Phase 2 | Academic and Community Cancer Research United | 25 mi |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | N/A | University of Colorado, Denver | 25 mi |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments | Phase 1/2 | GlaxoSmithKline | 25 mi |
| A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | Phase 1/2 | Iovance Biotherapeutics, Inc. | 25 mi |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | 25 mi |
| Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer | N/A | H. Lee Moffitt Cancer Center and Research Institute | 25 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | 25 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | 25 mi |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | Phase 2 | AbbVie | 25 mi |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors | Phase 1/2 | Perspective Therapeutics | 25 mi |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | 25 mi |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Phase 2 | Pulmotect, Inc. | 25 mi |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Phase 1 | Newave Pharmaceutical Inc | 25 mi |
| Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma | — | Case Western Reserve University | 25 mi |
| Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | Phase 2 | Joshua Zeidner | 25 mi |
| Medically Tailored Meals for Kids | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 | — | University of Washington | 25 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) | N/A | National Cancer Institute (NCI) | 25 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | Phase 1/2 | AbbVie | 25 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | 25 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Phase 3 | Eli Lilly and Company | 25 mi |
| Transformative Research in Diabetic Nephropathy | — | University of Pennsylvania | 25 mi |
| Rare and Atypical Diabetes Network | — | University of South Florida | 25 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | 25 mi |
| Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | 25 mi |
| Preventing Type 2 Diabetes in Black Emergent Adult | N/A | University of North Carolina, Chapel Hill | 25 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 25 mi |
| Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART | N/A | University of North Carolina, Chapel Hill | 25 mi |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 25 mi |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | 25 mi |
| Expanding the Support of Family Caregivers of Diverse Patients With Cancer and Diabetes | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | 25 mi |
| Food as Medicine for HIV and Diabetes | N/A | University of North Carolina, Chapel Hill | 25 mi |
| FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) | Phase 2 | Sanofi | 25 mi |
| HLA Demographics Study in Adults With Type 1 Diabetes | — | GentiBio, Inc | 25 mi |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | 25 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | 25 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | 25 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | 25 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | 25 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 25 mi |
| REAL-Fam Feasibility Study for Youth Diabetes Management | N/A | University of North Carolina, Chapel Hill | 25 mi |
| CGM for Management of Type 2 Diabetes in Pregnancy | N/A | University of Alabama at Birmingham | 25 mi |
| Psilocybin-Assisted Therapy in Treatment-Resistant Depression | Phase 3 | University of North Carolina, Chapel Hill | 25 mi |
| Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS) | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive Disorder | N/A | Pulvinar Neuro, LLC | 25 mi |
| Examining the Effects of Estradiol on Neural and Molecular Response to Reward | Phase 4 | University of North Carolina, Chapel Hill | 25 mi |
| Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression | Phase 4 | University of North Carolina, Chapel Hill | 25 mi |
| Neuroscience of Psychotherapy for Depression | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Adolescent Mood During Puberty and Testosterone | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Improving PCP Advance Care Planning for People With ADRD | N/A | University of Pittsburgh | 25 mi |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease | Phase 2 | Novartis Pharmaceuticals | 25 mi |
| Connect-Home: Alzheimer's Disease and Related Dementias | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Implement and Test Visual Consent Template and Process | N/A | Washington University School of Medicine | 25 mi |
| Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults | N/A | University of North Carolina, Chapel Hill | 25 mi |
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight | Phase 3 | Novo Nordisk A/S | 25 mi |
| FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing) | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | 25 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | 25 mi |
| Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes | N/A | 3ive Labs | 25 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | 25 mi |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | 25 mi |
| Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry | — | University of Colorado, Denver | 25 mi |
| The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study | Phase 2 | University of North Carolina, Chapel Hill | 25 mi |
| Physical Activity and Community EmPOWERment Project | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | 25 mi |
| Depression, Aging, Stress and Heart Health Study | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease | — | University of North Carolina, Chapel Hill | 25 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | 25 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | 25 mi |
| Healthy Living Anson Study | N/A | University of North Carolina, Chapel Hill | 25 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | 25 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | 25 mi |
| Individualizing Treatment for Asthma in Primary Care (Full Study) | Phase 4 | DARTNet Institute | 25 mi |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | 25 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma | Phase 3 | AstraZeneca | 25 mi |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) | Phase 3 | Sanofi | 25 mi |
| Gait Rehabilitation to Treat FastOA | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Knee Biofeedback Rehabilitation Through Game Therapy | N/A | Barron Associates, Inc. | 25 mi |
| Addressing Neuromuscular Deficits for Improved Outcomes in Ankle Rehabilitation | N/A | Phillip Gribble | 25 mi |
| Primary Subtalar Arthrodesis for Calcaneal Fractures | N/A | Wake Forest University Health Sciences | 25 mi |
| The Osteoarthritis Prevention Study | N/A | Wake Forest University | 25 mi |
| Preventing Injured Knees From osteoArthritis: Severity Outcomes | Phase 2 | Brigham and Women's Hospital | 25 mi |
| Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury | N/A | University of North Carolina, Chapel Hill | 25 mi |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | Phase 3 | AbbVie | 25 mi |
| A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease | Phase 1/2 | Genentech, Inc. | 25 mi |
| Effects of "Alliance180 Program" on Well-Being | N/A | University of North Carolina, Chapel Hill | 25 mi |
| TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age | — | State University of New York at Buffalo | 25 mi |
| Comparing Cognitive-Behavioral Therapy Versus Mindfulness-Based Therapy for Autistic Adults | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Adverse Adolescent Pathways to Substance Use | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Teachers Leading the Front Lines - North Carolina (Tealeaf-NC) | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Animal Assisted Therapy in Pediatric Dentistry | N/A | University of North Carolina, Chapel Hill | 25 mi |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | 25 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | 25 mi |
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | Phase 1/2 | Cabaletta Bio | 25 mi |
| A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | Phase 1 | CRISPR Therapeutics | 25 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 25 mi |
| A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 25 mi |
| The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | Phase 2 | Children's Hospital Medical Center, Cincinnati | 25 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | AstraZeneca | 25 mi |
| Lupus Landmark Study: A Prospective Registry and Biorepository | — | Lupus Research Alliance | 25 mi |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | Phase 1/2 | AstraZeneca | 25 mi |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Phase 2 | Darcy Krueger | 25 mi |
| A Study of AZD0120 in Autoimmune Diseases | Phase 1 | AstraZeneca | 25 mi |
| Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Dissemination of BREASTChoice AIM1-B | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Phase 2 | Dana-Farber Cancer Institute | 25 mi |
| PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients | — | Endomagnetics Ltd. | 25 mi |
| Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Comparison of CE-DBT and MRI in Patients With Known Breast Lesions | Early 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Phase 2 | Ana C Garrido-Castro, MD | 25 mi |
| A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | 25 mi |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | Phase 1 | University of Texas Southwestern Medical Center | 25 mi |
| A Novel Approach Utilizing Organ Specific Age Proteomics | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | 25 mi |
| Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST) | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Promoting Resilience in Women With Breast Cancer (PRISM -MBC) | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Nutrition Awareness Among Women With Non-Metastatic Breast Cancer | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | 25 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | 25 mi |
| Adaptation of a Values Assessment Tool | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | Phase 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Phase 3 | Pfizer | 25 mi |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Early 1 | Presage Biosciences | 25 mi |
| Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| BREAST Choice Decision Tool R21 - AIM2 | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| ETHAN - ET for Male BC | Phase 2 | Jose Pablo Leone | 25 mi |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study | Phase 2 | AstraZeneca | 25 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 25 mi |
| Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | Early 1 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | 25 mi |
| PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival | N/A | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study | — | Invenio Imaging Inc. | 25 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | 25 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | 25 mi |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | Janux Therapeutics | 25 mi |
| A Study of NX-1607 in Adults With Advanced Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 25 mi |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Phase 2 | Apollomics Inc. | 25 mi |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | 25 mi |
| Study of Trilaciclib and Lurbinectidin | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Eli Lilly and Company | 25 mi |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | 25 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | 25 mi |
| Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study | — | Tempus AI | 25 mi |
| UNC Pleural Fluid Registry | — | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Phase 1/2 | Phanes Therapeutics | 25 mi |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | — | Elephas | 25 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | 25 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | 25 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | 25 mi |
| Drug-Induced Liver Injury (DILI) Network Retrospective | — | Duke University | 25 mi |
| DILIN - Prospective Study | — | Duke University | 25 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | 25 mi |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Phase 2 | Coherus Oncology, Inc. | 25 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | 25 mi |
| The Vanguard Study: Testing a New Way to Screen for Cancer | N/A | National Cancer Institute (NCI) | 25 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | 25 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | 25 mi |
| Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | Phase 2 | UNC Lineberger Comprehensive Cancer Center | 25 mi |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | Phase 4 | Guerbet | 25 mi |
| Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform | — | Elephas | 25 mi |
| Health Education Approach to Lung Screening | N/A | Virginia Commonwealth University | 26 mi |
| Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | 33 mi |
| Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | 37 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | 37 mi |
| Weight Management After Cancer for Survivors in Rural Communities | N/A | Duke University | 40 mi |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | 41 mi |
| Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | Phase 1/2 | Starton Therapeutics, Inc | 41 mi |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Phase 3 | Epizyme, Inc. | 41 mi |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Phase 3 | Pfizer | 41 mi |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | Phase 2 | Janssen Research & Development, LLC | 41 mi |
| Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | 41 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 41 mi |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | 45 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | 45 mi |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | Janssen Research & Development, LLC | 45 mi |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | 45 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | 45 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 45 mi |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | Phase 2 | National Cancer Institute (NCI) | 45 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | 45 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | 45 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | 45 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | 45 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 45 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | 45 mi |
| Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays | — | Tempus AI | 45 mi |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | Phase 2 | Alliance for Clinical Trials in Oncology | 45 mi |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Phase 3 | Alliance for Clinical Trials in Oncology | 45 mi |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | 45 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 45 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | 45 mi |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) | Phase 3 | Janssen Research & Development, LLC | 45 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | 45 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | 45 mi |
| Vitamin D for Prostate Endocrine Therapy | Phase 3 | University of Rochester | 49 mi |
| Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC) | Phase 4 | Cellution Biologics | 49 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | 49 mi |
| CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms | N/A | Johns Hopkins University | 49 mi |
| Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) | N/A | ECOG-ACRIN Cancer Research Group | 50 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | 50 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | 50 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | 50 mi |